Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Kern, Silke ^a   Skoog, Ingmar ^a   Östling, Svante ^a   Kern, Jürgen ^a   Börjesson Hanson, Anne ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; DEMENTIA; DSM-III-R; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PEPTIC ULCER; STOMACH ULCER; SWEDEN; TREATMENT RESPONSE;

EID: 84869825719     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001288     Document Type: Article

References (36)

1. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci 2010;1207:155-62.
2. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;14:973-9.
3. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;7:396-403.
4. Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009;22:1899-905.
5. Henderson AS, Jorm AF, Christensen H, et al. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997;9:926-30.
6. in t' Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;21:1515-21.
7. Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008;7:896-905.
8. Grodstein F, Skarupski KA, Bienias JL, et al. Anti-inflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology 2008;1:45-50.
9. Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County Study. Neurology 2000;11:2066-71.
10. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;21:2819-26.
11. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002;59:880-6.
12. Nilsson SE, Johansson B, Takkinen S, et al. Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years. Eur J Clin Pharmacol 2003;4:313-19.
13. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;2:517-84.
14. Barnett H, Burrill P, Iheanacho I. Don't use aspirin for primary prevention of cardiovascular disease. BMJ 2010;340:c1805.
15. Vane JR. Introduction: mechanism of action of NSAIDs. Br J Rheumatol 1996;35(Suppl 1):1-3.
16. Jonker C, Comijs HC, Smit JH. Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 2003;4:583-8.
17. Sturmer T, Glynn RJ, Field TS, et al. Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;7:683-91.
18. Waldstein SR, Wendell CR, Seliger SL, et al. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc 2010;1:38-43.
19. Kang JH, Cook N, Manson J, et al. Low dose aspirin and cognitive function in the women's health study cognitive cohort. BMJ 2007;7601:987-94.
20. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;6:743-53.
21. Bengtsson C, Blohme G, Hallberg L, et al. The study of women in Gothenburg 1968-1969-a population study. General design, purpose and sampling results. Acta Med Scand 1973;4:311-18.
22. Karlsson B, Klenfeldt IF, Sigstrom R, et al. Prevalence of social phobia in non-demented elderly from a swedish population study. Am J Geriatr Psychiatry 2009;2:127-35.
23. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;3:153-8.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;3:189-98.
25. Association AP. Diagnostic and statistical manual of mental disorders. 3rd revised edn. 1987.
26. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
27. Waldstein SR, Wendell CR, Seliger SL, et al. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc 2010;1:38-43.
28. Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;3:626-32.
29. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8.
30. Ridker PM, Hennekens CH, Tofler GH, et al. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996;2:209-12.
31. Pomponi MF, Gambassi G, Pomponi M, et al. Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer's disease? Ageing Res Rev 2010;1:124-31.
32. Association AH. Recommendation guide to primary prevention of cardiosvascular diseases in adults. 2010.
33. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;2:517-84.
34. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;24:2694-701.
35. Gorelick PB. Cerebral microbleeds: evidence of heightened risk associated with aspirin use. Arch Neurol 2009;6:691-3.
36. Vernooij MW, Haag MD, van der Lugt A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 2009;6:714-20.